Merck, AZ asthma pills as good as inhalers; Allergan Q1 results beat on Botox growth;

@FiercePharma: Is a Bayer 'merger of equals' in the stars? Story | Follow @FiercePharma

> Asthma treatments known as leukotriene receptor antagonists, such as Accolate from AstraZeneca and Singulair from Merck, are easier to use and just as effective as conventional inhaler treatments, a study found. Report

> Allergan reported higher-than-expected first-quarter results, fueled by strong sales growth of its Botox anti-wrinkle medicine and its eye care and skin care products. News

> Chile's CFR Pharmaceuticals priced an initial public offering of more than 2 billion shares at 85 pesos per share. Story

> Ranbaxy Laboratories shares fell the most in more than six weeks in Mumbai trading after Fortune Magazine said U.S. federal prosecutors are negotiating a dispute settlement that could cost the company more than $1 billion. Article

> The FDA released its final guidance to firms that manufacture, market or distribute over-the-counter (OTC) liquid drug products packaged with cups, droppers, syringes and spoons to measure and dispense the doses of medication. Item

> Mylan Pharmaceuticals launched its generic version of Endo Pharmaceuticals' pain tablet Percodan. Release

> Onyx Pharmaceuticals said its first-quarter loss swelled, as operating costs rose and the company absorbed an expense tied to its acquisition of the cancer drug developer Proteolix. Report

> Albany Molecular Research posted a modest net loss on costs and restructuring charges, but saw revenue grow considerably thanks to contract manufacturing and royalties. Story

> Pfizer Animal Health has acknowledged a link between its Pregsure BVD vaccine and Bovine Neonatal Pancytopaenia (BNP), commonly known as Bleeding Calf Syndrome, Farmers Weekly says. News

Biotech News

 @FierceBiotech:  Novartis CEO outlines a winning drug development strategy. News | Follow @FierceBiotech 

 @JohnCFierce: Molecular Partners AG reports it got a $420M deal with Allergan on opthalmic program. $45M upfront. Story | Follow @JohnCFierce

> StemCells axes 20 staffers as it conserves cash for trial work. Story

> Actelion shareholders hand Elliott-backed insurgents a defeat. News 

> INC snags Kendle's global CRO operations for $232M in cash. Article 

> CIRM provides $25M for Geron's pioneering stem cell trial. Article 

Vaccines News

> Gates gives $8.9M to fund new malaria vaccine approach. Story 

> Sweden's Isconova buys Nordic Vaccine. News 

> Government funds Ebola, Marburg vaccine. Report 

> OncoPep vax aims to stop multiple myeloma before it starts. Article

> UCF Professor wins Gates grant for needle-free vaccines. Story 

Manufacturing News

> Specialty distributor skillset quantified. News

> Drug shortages suggest business niche. Article

> QA neglect jeopardizes Ranbaxy's future revenue. Story

> Novasep, Solvias ingenuity trump offshoring. Report

> Expert hints open standards may help Pfizer's PAT. News

And Finally... Researchers lately have learned that serotonin plays an impressive number of critical roles throughout the body, both below the neck and above it, and from the earliest days of prenatal pre-sentience. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.